Drugs News and Research

RSS

EU-India free-trade negotiations could limit access to affordable, generic drugs, advocacy group says

The advocacy group Medecins Sans Frontieres (MSF) recently warned that free-trade negotiations between the EU and India could limit access to "affordable generic drugs" for people in India and the rest of the developing world, Reuters reports.

17 Mar 2010

Key cellular defect in protein synthesis can lead to cancer susceptibility

UCSF researchers have discovered that a key cellular defect that disturbs the production of proteins in human cells can lead to cancer susceptibility. The scientists also found that a new generation of inhibitory drugs offers promise in correcting this defect.

17 Mar 2010

False Claims Act allegations over marketing of morphine-based drug Kadian: Alpharma to pay $42.5M

American pharmaceutical manufacturer Alpharma Inc. has agreed to pay $42.5 million to resolve False Claims Act allegations in connection with the marketing of the morphine-based drug, Kadian, the Justice Department announced today. The settlement resolves allegations that, between January 1, 2000 and December 29, 2008, Alpharma paid health care providers to induce them to promote or prescribe Kadian, and made misrepresentations about the safety and efficacy of the drug, which is used to treat chronic moderate to severe pain.

17 Mar 2010

Unapproved nitroglycerin tablets: FDA orders Glenmark Generics and Konec to stop marketing

The U.S. Food and Drug Administration today ordered Glenmark Generics of Mahwah, N.J., and Konec Inc. of Tucson, Ariz., to stop marketing unapproved nitroglycerin tablets. The tablets are placed under the tongue to relieve chest pain or to stop a heart attack and are marketed in 0.3 mg, 0.4 mg, and 0.6 mg dosages.

17 Mar 2010

Acetaminophen safe and effective for reducing postpartum pain

For many mothers of newborns, lingering pain from the delivery can interfere with their first days with their infant. A recent review examined whether over-the-counter medications containing acetaminophen - Tylenol for example − provided adequate relief for such pain and concluded that they are effective.

17 Mar 2010

Quinnova Pharmaceuticals introduces NEOSALUS CREAM for chronic inflammatory skin conditions

Quinnova Pharmaceuticals, Inc., a specialty pharmaceutical company that develops and markets novel topical delivery platform-based prescription drugs, announced the launch of its NEOSALUSTM CREAM. NEOSALUS CREAM, the latest addition to Quinnova’s NEOSALUS brand, is a prescription product with anti-inflammatory properties that can be used without age or long-term use restrictions for the treatment of a variety of chronic inflammatory skin conditions like atopic dermatitis, contact dermatitis, and hand eczema.

16 Mar 2010

Blocking RhoA enzyme increases survival in SMA mouse model

Scientists from the Ottawa Hospital Research Institute (OHRI) and the University of Ottawa have identified a promising new approach for developing drugs to treat Spinal muscular atrophy (SMA), the leading inherited cause of death in infants and toddlers. Dr. Rashmi Kothary and his doctoral student Melissa Bowerman have found that an enzyme called RhoA is overly active in a mouse model of the disease and blocking this enzyme can greatly increase survival. The study is published in Human Molecular Genetics.

16 Mar 2010

Viron Therapeutics' VT-346 anti-TNF protein exhibits positive results in transgenic mouse model for arthritis

Viron Therapeutics Inc. announced that VT-346, an anti-TNF protein therapeutic, demonstrated positive results in a pivotal proof of concept study in the gold standard transgenic mouse model for arthritis. VT-346 achieved a statistically significant, dose dependent impact in this preclinical model of arthritis and prevented deterioration due to disease in terms of weight gain, arthritic score and pathology parameters. VT-346 had particularly strong protective effects on therapeutically-important bone and cartilage damage in this model.

16 Mar 2010

Promedior raises $12M in Series C financing

Promedior, Inc., a clinical stage biotechnology company developing novel therapies to treat inflammatory and fibrotic diseases, today announced that it has raised $12 million in a Series C financing round. Forbion Capital Partners led the round, with participation from existing investors Morgenthaler Ventures, HealthCare Ventures, Polaris Venture Partners, and Easton Capital. The Series C financing brings the total capital raised by Promedior over the past year to $27 million.

16 Mar 2010

Aging and Alzheimer's disease: Novel brain imaging technologies help create new insights

The emergence of multiple new brain imaging technologies and the combined application of these new approaches is helping to create new insights into aging and Alzheimer's disease. One of the hallmarks of Alzheimer's disease is the deposition of amyloid beta protein in clumps or "plaques" within the brain. These plaques can be measured in humans with PET scans that use a chemical marker or radiotracer called 11C-PIB.

16 Mar 2010

BeaconEquity.com announces investment report featuring Intellipharmaceutics International

BeaconEquity.com announces an investment report featuring Intellipharmaceutics International Inc. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

16 Mar 2010

PERSEUS clinical program demonstrates positive results of TAXUS Element Paclitaxel-Eluting Stent System

Boston Scientific Corporation today announced 12-month results from its PERSEUS clinical program that demonstrated positive safety and efficacy outcomes in workhorse lesions for the platinum chromium TAXUS® Element™ Paclitaxel-Eluting Stent System compared to the TAXUS® Express2™ Paclitaxel-Eluting Stent System.

16 Mar 2010

Research suggests anti-cancer drugs can help treat infectious diseases

Drugs increasingly used to treat cancer could have a major impact on a wide range of infectious diseases, according to new research.

16 Mar 2010

Minimal improvements made in survival rates of AYA population with cancer

Despite cancer survival rates increasing dramatically for children and older adults in the last 20 years, there has been minimal improvement in the survival rates in the Adolescent and Young Adult (AYA) population, an age range defined as 15 – 29 years by the presenters.

16 Mar 2010

Banana lectin discovery may lead to potential new treatments for preventing sexual transmission of HIV

A potent new inhibitor of HIV, derived from bananas, may open the door to new treatments to prevent sexual transmission of HIV, according to a University of Michigan Medical School study published this week.

16 Mar 2010

Study suggests HuR gene plays a critical role in inducing cells' inflammatory response

To understand the role of inflammation in cardiovascular and other diseases, it is essential to identify and characterize genes that induce an inflammatory response in the body -- and the genes that regulate them.

16 Mar 2010

COSE statement on health care reform

While a popular target, beating up on health insurance companies will do little to provide changes in insurance costs. Insurance profits and overhead are just a small part of the insurance bill. It's the underlying medical services, technology, tests and drugs that drive cost.

16 Mar 2010

Long-term tobacco dependence may affect memory and thinking in women

Men and women with a history of alcohol abuse may not see long-term negative effects on their memory and thinking, but female smokers do, a new study suggests.

16 Mar 2010

Differences in brain's reward system may underlie vulnerability to psychopathy: Study

Normal individuals who scored high on a measure of impulsive/antisocial traits display a hypersensitive brain reward system, according to a brain imaging study by researchers at Vanderbilt University. The findings provide the first evidence of differences in the brain's reward system that may underlie vulnerability to what's typically referred to as psychopathy.

16 Mar 2010

Tips for reducing LDL cholesterol

Cardiovascular disease is the No.1 killer in North America. And high cholesterol is one of the primary risk factors of coronary heart disease and stroke. According to the Heart and Stroke Foundation, almost 40% of Canadian adults are classified as having high blood cholesterol levels.

16 Mar 2010

Drugs News and Research

EU-India free-trade negotiations could limit access to affordable, generic drugs, advocacy group says

Key cellular defect in protein synthesis can lead to cancer susceptibility

False Claims Act allegations over marketing of morphine-based drug Kadian: Alpharma to pay $42.5M

Unapproved nitroglycerin tablets: FDA orders Glenmark Generics and Konec to stop marketing

Acetaminophen safe and effective for reducing postpartum pain

Quinnova Pharmaceuticals introduces NEOSALUS CREAM for chronic inflammatory skin conditions

Blocking RhoA enzyme increases survival in SMA mouse model

Viron Therapeutics' VT-346 anti-TNF protein exhibits positive results in transgenic mouse model for arthritis

Promedior raises $12M in Series C financing

Aging and Alzheimer's disease: Novel brain imaging technologies help create new insights

BeaconEquity.com announces investment report featuring Intellipharmaceutics International

PERSEUS clinical program demonstrates positive results of TAXUS Element Paclitaxel-Eluting Stent System

Research suggests anti-cancer drugs can help treat infectious diseases

Minimal improvements made in survival rates of AYA population with cancer

Banana lectin discovery may lead to potential new treatments for preventing sexual transmission of HIV

Study suggests HuR gene plays a critical role in inducing cells' inflammatory response

COSE statement on health care reform

Long-term tobacco dependence may affect memory and thinking in women

Differences in brain's reward system may underlie vulnerability to psychopathy: Study

Tips for reducing LDL cholesterol

Drug Discovery - Second Edition eBook

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News